NHS England and Merck have reached an agreement that people eligible for treatment can access Mavenclad (cladribine) immediately.
Mavenclad (cladribine) has been approved as a treatment for people with highly active relapsing MS on the NHS in England and Wales.
Ibudilast slowed down the loss of brain volume in primary and secondary progressive MS by almost one half compared to placebo according to results presented at ECTRIMS 2017.
Results of a small study suggest that clemastine, a drug used to treat allergies, may repair damage to myelin in the optic nerve of people with MS.
The MS Trust and NHS Lanarkshire are delighted to announce that they have worked together to recruit two new MS specialist nurses, plus a part-time neurology nurse, to support the 1,200 people living with MS in Lanarkshire. The new nurses will begin work later in September.
The European Commission (EC) has granted marketing authorization for cladribine (Mavenclad) for the treatment of adults with highly active relapsing multiple sclerosis.
The European Medicines Agency has recommended that a licence should be granted for cladribine (Mavenclad) for the treatment of highly active relapsing multiple sclerosis.
A headline in the Daily Mirror makes claims for an experimental treatment that are not yet backed up by research.
The Neurological Alliance, the coalition of 80 organisations working for people with neurological conditions, including the MS Trust, has published a manifesto for neurology services in England.
The launch of a trial involving more than 1000 people with secondary progressive MS (SPMS) has been announced. The trial will investigate whether simvastatin can slow down disability progression.